The situations and strategies of amyloid-&beta;-directed passive immunotherapy for Alzheimer's disease

doi:10.3969/j.issn.1672-6731.2019.12.014

Abstract

Abstract:

It is widely believed that amyloid β-protein (Aβ) plays a core role in the pathogenesis of Alzheimer's disease (AD). Thus A β is one of main targets in the therapeutic explorations for AD. Currently, clearance of A β by passive immunotherapy is an important strategy for the treatment of AD. However, no consistent conclusions have been obtained from various clinical trails. We summarize the current situations of A β-directed passive immunotherapy for AD, and speculate that the failure of A β-directed passive immunotherapy for AD may be related to the intrinsic characteristics of A β-IgG glycosylation. Therefore, modifications of N-glycosylation on the Fc domain of A β-IgG and using a sequential administration mode of proinflammation-antiinflammation may be an effective strategy for passive immunotherapy for AD.

Key words: Alzheimer disease, Amyloid beta-peptides, Immunization, passive, Review

摘要：

β-淀粉样蛋白（Aβ）既是阿尔茨海默病发病机制中的重要病因，又是治疗的关键靶点之一。采取被动免疫途径清除脑组织Aβ是目前颇受临床关注的治疗策略。然而，各项临床试验至今尚未获得一致性的结论。对其研究现状的分析表明，Aβ被动免疫治疗失败的原因可能与Aβ-IgG免疫复合物所固有的糖基化修饰有关。因此，改良Aβ-IgG Fc片段N-糖基化修饰、采取促炎症反应-抗炎症反应序贯给药模式，可能是一种有效的被动免疫治疗策略。

关键词: 阿尔茨海默病, 淀粉样β肽类, 免疫法, 被动, 综述

LI Ya, ZHANG An-ni, WU Xu-ling, ZHAO Yan, CAI Gang, HE Dian. The situations and strategies of amyloid-β-directed passive immunotherapy for Alzheimer's disease[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2019, 19(12): 987-993.

李娅, 张安妮, 吴旭玲, 赵艳, 蔡刚, 贺电. β-淀粉样蛋白被动免疫治疗阿尔茨海默病的现状与策略[J]. 中国现代神经疾病杂志, 2019, 19(12): 987-993.

/ / Recommend / Download Citations

URL: https://journal11.magtechjournal.com/cjcnn/EN/10.3969/j.issn.1672-6731.2019.12.014

https://journal11.magtechjournal.com/cjcnn/EN/Y2019/V19/I12/987

References

[1] Jia J, Wang F, Wei C, Zhou A, Jia X, Li F, Tang M, Chu L, Zhou Y, Zhou C, Cui Y, Wang Q, Wang W, Yin P, Hu N, Zuo X, Song H, Qin W, Wu L, Li D, Jia L, Song J, Han Y, Xing Y, Yang P, Li Y, Qiao Y, Tang Y, Lv J, Dong X. The prevalence of dementia in urban and rural areas of China[J]. Alzheimers Dement, 2014, 10:1-9.
[2] Alzheimer's Association. 2016 Alzheimer's disease facts and figures[J]. Alzheimers Dement, 2016, 12:459-509.
[3] Zeng XY, Qi JL, Yin P, Wang LJ, Liu YN, Liu JM, Zhou MG, Liang XF. Disease burden report of China and provincial administrative regions from 1990 to 2016[J]. Zhongguo Xun Huan Za Zhi, 2018, 33:1147-1158.[曾新颖, 齐金蕾, 殷鹏, 王黎君, 刘韫宁, 刘江美, 周脉耕, 梁晓峰. 1990~2016年中国及省级行政区疾病负担报告[J]. 中国循环杂志, 2018, 33:1147-1158.]
[4] Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R;Contributors. NIA-AA research framework:toward a biological definition of Alzheimer's disease[J]. Alzheimers Dement, 2018, 14:535-562.
[5] Fernandez MA, Klutkowski JA, Freret T, Wolfe MS. Alzheimer prsnilin-1 mutations dramatically reduce trimming of long amyloid β-peptides (A β) by γ-secretase to increase 42-to-40-residue Aβ[J]. J Biol Chem, 2014, 289:31043-31052.
[6] Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years[J]. EMBO Mol Med, 2016, 8:595-608.
[7] Mohamed T, Shakeri A, Rao PP. Amyloid cascade in Alzheimer's disease:recent advances in medicinal chemistry[J]. Eur J Med Chem, 2016, 113:258-272.
[8] Knight EM, Kim SH, Kottwitz JC, Hatami A, Albay R, Suzuki A, Lublin A, Alberini CM, Klein WL, Szabo P, Relkin NR, Ehrlich M, Glabe CG, Gandy S, Steele JW. Effective anti -Alzheimer A β therapy involves depletion of specific A β oligomer subtypes[J]. Neurol Neuroimmunol Neuroinflamm, 2016, 3:E237.
[9] Wu J, Li L. Autoantibodies in Alzheimer's disease:potential biomarkers, pathogenic roles, and therapeutic implications[J]. J Biomed Res, 2016, 30:361-372.
[10] Du Y, Dodel R, Hampel H, Buerger K, Lin S, Eastwood B, Bales K, Gao F, Moeller HJ, Oertel W, Farlow M, Paul S.Reduced levels of amyloid beta-peptide antibody in Alzheimer disease[J]. Neurology, 2001, 57:801-805.
[11] Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals[J]. Exp Gerontol, 2002, 37:943-948.
[12] Song MS, Mook-Jung I, Lee HJ, Min JY, Park MH. Serum anti-amyloid-beta antibodies and Alzheimer's disease in elderly Korean patients[J]. J Int Med Res, 2007, 35:301-306.
[13] Brettschneider S, Morgenthaler NG, Teipel SJ, Fischer-Schulz C, Bürger K, Dodel R, Du Y, Möller HJ, Bergmann A, Hampel H. Decreased serum amyloid beta (1-42) autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta (1-42) peptide[J]. Biol Psychiatry, 2005, 57:813-816.
[14] Moir RD, Tseitlin KA, Soscia S, Hyman BT, Irizarry MC, Tanzi RE. Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients[J]. J Biol Chem, 2005, 280:17458-17463.
[15] Hyman BT, Smith C, Buldyrev I, Whelan C, Brown H, Tang MX, Mayeux R. Autoantibodies to amyloid-beta and Alzheimer's disease[J]. Ann Neurol, 2001, 49:808-810.
[16] Baril L, Nicolas L, Croisile B, Crozier P, Hessler C, Sassolas A, McCormick JB, Trannoy E. Immune response to Abeta-peptides in peripheral blood from patients with Alzheimer's disease and control subjects[J]. Neurosci Lett, 2004, 355:226-230.
[17] Klaver AC, Coffey MP, Smith LM, Bennett DA, Finke JM, Dang L, Loeffler DA. ELISA measurement of specific non-antigen -bound antibodies to Aβ1-42 monomer and soluble oligomers in sera from Alzheimer's disease, mild cognitively impaired, and noncognitively impaired subjects[J]. J Neuroinflammation, 2011, 8:93.
[18] Gustaw KA, Garrett MR, Lee HG, Castellani RJ, Zagorski MG, Prakasam A, Siedlak SL, Zhu X, Perry G, Petersen RB, Friedland RP, Smith MA. Antigen-antibody dissociation in Alzheimer disease:a novel approach to diagnosis[J]. J Neurochem, 2008, 106:1350-1356.
[19] Gruden MA, Davidova TB, Malisauskas M, Sewell RD, Voskresenskaya NI, Wilhelm K, Elistratova EI, Sherstnev VV, Morozova-Roche LA. Differential neuroimmune markers to the onset of Alzheimer's disease neurodegeneration and dementia:autoantibodies to Abeta (25-35) oligomers, S100b and neurotransmitters[J]. J Neuroimmunol, 2007, 186:181-192.
[20] Wang YJ, Liu YH, Zeng F, Liu CH, Wang L, Deng J, Zhou HD. The role of anti-Aβ autoantibodies in Alzheimer's disease[C]. Abstract Proceedings the 17th National Neurology Conference of Chinese Medical Association, Xiamen:Chinese Medical Association, 2014:487.[王延江, 刘雨辉, 曾凡, 刘成惠, 王琳, 邓娟, 周华东. 抗Aβ自身抗体在阿尔茨海默病中的作用[C]. 中华医学会第十七次全国神经病学学术会议论文集, 厦门:中华医学会, 2014:487.]
[21] Gustaw-Rothenberg KA, Siedlak SL, Bonda DJ, Lerner A, Tabaton M, Perry G, Smith MA. Dissociated amyloid-beta antibody levels as a serum biomarker for the progression of Alzheimer's disease:a population-based study[J]. Exp Gerontol, 2010, 45:47-52.
[22] Maftei M, Thurm F, Schnack C, Tumani H, Otto M, Elbert T, Kolassa IT, Przybylski M, Manea M, von Arnim CA. Increased levels of antigen-bound β-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer's disease patients[J]. PLoS One, 2013, 8:E68996.
[23] Qu BX, Gong Y, Moore C, Fu M, German DC, Chang LY, Rosenberg R, Diaz-Arrastia R. Beta-amyloid auto-antibodies are reduced in Alzheimer's disease[J]. J Neuroimmunol, 2014, 274:168-173.
[24] Sha SJ, Deutsch GK, Tian L, Richardson K, Coburn M, Gaudioso JL, Marcal T, Solomon E, Boumis A, Bet A, Mennes M, van Oort E, Beckmann CF, Braithwaite SP, Jackson S, Nikolich K, Stephens D, Kerchner GA, Wyss-Coray T. Safety, tolerability, and feasibility of young plasma infusion in the plasma for alzheimer symptom amelioration study:arandomized clinical trial[J]. JAMA Neurol, 2019, 76:35-40.
[25] Wang T, Xie XX, Ji M, Wang SW, Zha J, Zhou WW, Yu XL, Wei C, Ma S, Xi ZY, Pang GL, Liu RT. Naturally occurring autoantibodies against A β oligomers exhibited more beneficial effects in the treatment of mouse model of Alzheimer's disease than intravenous immunoglobulin[J]. Neuropharmacology, 2016, 105:561-576.
[26] Marciani DJ. A retrospective analysis of the Alzheimer's disease vaccineprogress:the critical need for new development strategies[J]. J Neurochem, 2016, 137:687-700.
[27] Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease[J].Nat Med, 2000, 6:916-919.
[28] DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease[J]. Proc Natl Acad Sci USA, 2001, 98:8850-8855.
[29] Lemere CA. Immunotherapy for Alzheimer's disease:hoops and hurdles[J]. Mol Neurodegener, 2013, 8:36.
[30] Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu -Seifert H, Mohs R, Alzheimer's Disease Cooperative Study Steering Committee; Solanezumab Study Group. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease[J]. N Engl J Med, 2014, 370:311-321.
[31] Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapi-neuzumab 301 and 302 Clinical Trial Investigators. Two phase 3 trials of bapineuzumab in mild-to -moderate Alzheimer's disease[J]. N Engl J Med, 2014, 370:322-333.
[32] Kohyama K, Matsumoto Y. Alzheimer's disease and immunotherapy:what is wrong with clinical trials[J]?Immunotargets Ther, 2015, 4:27-34.
[33] Wang YJ. Alzheimer disease:lessons from immunotherapy for Alzheimer disease[J]. Nat Rev Neurol, 2014, 10:188-189.
[34] Szabo P, Mujalli DM, Rotondi ML, Sharma R, Weber A, Schwarz HP, Weksler ME, Relkin N. Measurement of anti-beta amyloid antibodies in human blood[J]. J Neuroimmunol, 2010, 227:167-174.
[35] Moreth J, Mavoungou C, Schindowski K. Passive anti-amyloid immunotherapy in Alzheimer's disease:what are the most promising targets[J]? Immun Ageing, 2013, 10:18.
[36] Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes:from structure to effector functions[J]. Front Immunol, 2014, 5:520.
[37] Anthony RM, Wermeling F, Ravetch JV. Novel roles for the IgG Fc glycan[J]. Ann NY Acad Sci, 2012, 1253:170-180.
[38] Dodel R, Balakrishnan K, Keyvani K, Deuster O, Neff F, Andrei-Selmer LC, Röskam S, Stüer C, Al-Abed Y, Noelker C, Balzer-Geldsetzer M, Oertel W, Du Y, Bacher M. Naturally occurring autoantibodies against beta-amyloid:investigating their role in transgenic animal and in vitro models of Alzheimer's disease[J].J Neurosci, 2011, 31:5847-5854.
[39] Mengel D, Röskam S, Neff F, Balakrishnan K, Deuster O, Gold M, Oertel WH, Bacher M, Bach JP, Dodel R. Naturally occurring autoantibodies interfere with β-amyloid metabolism and improve cognition in a transgenic mouse model of Alzheimer's disease 24 h after single treatment[J]. Transl Psychiatry, 2013, 3:E236.
[40] Puli L, Pomeshchik Y, Olas K, Malm T, Koistinaho J, Tanila H.Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease[J]. J Neuroinflammation, 2012, 9:105.
[41] Relkin NR, Thomas RG, Rissman RA, Brewer JB, Rafii MS, van Dyck CH, Jack CR, Sano M, Knopman DS, Raman R, Szabo P, Gelmont DM, Fritsch S, Aisen PS; Alzheimer's Disease Cooperative Study. A phase 3 trial of Ⅳ immunoglobulin for Alzheimer disease[J]. Neurology, 2017, 88:1768-1775.
[42] Kile S, Au W, Parise C, Rose K, Donnel T, Hankins A, Chan M, Ghassemi A. IVIG treatment of mild cognitive impairment due to Alzheimer's disease:a randomized double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia[J]. J Neurol Neurosurg Psychiatry, 2017, 88:106-112.
[43] Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, Förster S, Winter Y, Bach JP, Popp J, Alferink J, Wiltfang J, Buerger K, Otto M, Antuono P, Jacoby M, Richter R, Stevens J,Melamed I, Goldstein J, Haag S, Wietek S, Farlow M, Jessen F. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease:a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial[J]. Lancet Neurol, 2013, 12:233-243.
[44] Arai H, Ichimiya Y, Shibata N, Nakajima T, Sudoh S, Tokuda T, Sujaku T, Yokokawa S, Hoshii N, Noguchi H, Bille A. Safety and tolerability of immune globulin intravenous (human), 10% solution in Japanese subjects with mild to moderate Alzheimer's disease[J]. Psychogeriatrics, 2014, 14:165-174.
[45] Perdivara I, Deterding LJ, Cozma C, Tomer KB, Przybylski M.Glycosylation profiles of epitope-specific anti-beta-amyloid antibodies revealed by liquid chromatography-mass spectrometry[J]. Glycobiology, 2009, 19:958-970.
[46] Kwon H, Crisostomo AC, Smalls HM, Finke JM. Anti-A β oligomer IgG and surface sialic acid in intravenous immunoglobulin:measurement and correlation with clinical outcomes in Alzheimer's disease treatment[J]. PLoS One, 2015, 10:E0120420.
[47] Lundström SL, Yang H, Lyutvinskiy Y, Rutishauser D, Herukka SK, Soininen H, Zubarev RA. Blood plasma IgG Fc glycans are significantly altered in Alzheimer's disease and progressive mild cognitive impairment[J]. J Alzheimers Dis, 2014, 38:567-579.
[48] Finke JM, Ayres KR, Brisbin RP, Hill HA, Wing EE, Banks WA. Antibody blood-brain barrier efflux is modulated by glycan modification[J]. Biochim Biophys Acta Gen Subj, 2017, 1861:2228-2239.
[49] Huang W, Giddens J, Fan SQ, Toonstra C, Wang LX.Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions[J]. J Am Chem Soc, 2012, 134:12308-12318.
[50] Kubota T, Niwa R, Satoh M, Akinaga S, Shitara K, Hanai N.Engineered therapeutic antibodies with improved effector functions[J]. Cancer Sci, 2009, 100:1566-1572.
[51] Li T, DiLillo DJ, Bournazos S, Giddens JP, Ravetch JV, Wang LX. Modulating IgG effector function by Fc glycan engineering[J]. Proc Natl Acad Sci USA, 2017, 114:3485-3490.
[52] Dekkers G, Treffers L, Plomp R, Bentlage AE, de Boer M, Koeleman CA, Lissenberg-Thunnissen SN, Visser R, Brouwer M, Mok JY, Matlung H, van den Berg TK, van Esch WJ, Kuijpers TW, Wouters D, Rispens T, Wuhrer M, Vidarsson G.Decoding the human immunoglobulin G-glycan repertoire reveals a spectrum of Fc-receptor-and complement-mediated -effector activities[J]. Front Immunol, 2017, 8:877.
[53] Peschke B, Keller CW, Weber P, Quast I, Lünemann JD. Fc -galactosylation of human immunoglobulin gamma isotypes improves C1q binding and enhances complement-dependent cytotoxicity[J]. Front Immunol, 2017, 8:646.
[54] Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation[J].Science, 2006, 313:670-673.
[55] Ahmed AA, Giddens J, Pincetic A, Lomino JV, Ravetch JV, Wang LX, Bjorkman PJ. Structural characterization of anti -inflammatory immunoglobulin G Fc proteins[J]. J Mol Biol, 2014, 426:3166-3179.
[56] Anthony RM, Kobayashi T, Wermeling F, Ravetch JV.Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway[J]. Nature, 2011, 475:110-113.
[57] Wang TT, Ravetch JV. Functional diversification of IgGs through Fc glycosylation[J]. J Clin Invest, 2019, 129:3492-3498.

Please choose a citation manager

Content to export

The situations and strategies of amyloid-β-directed passive immunotherapy for Alzheimer's disease

β-淀粉样蛋白被动免疫治疗阿尔茨海默病的现状与策略

RichHTML

PDF

Knowledge

Cited

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhi-yong TONG. Intracranial aneurysms and cerebral revascularization [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(8): 595-598.
[2]	Zhi-yong TONG. History of cerebral revascularization [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(8): 599-605.
[3]	Ling-ji JIN, Jun-wen HU, Yin LI, Lin WANG. Intracranial-intracranial bypass for the treatment of complex intracranial aneurysms: technical advances and surgical experience [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(8): 606-612.
[4]	Pei-xi LIU, Yuan SHI, Wei ZHU. Application of whole-region cerebral vascular bypass for intracranial aneurysms treatment in the flow diversion era [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(8): 613-618.
[5]	Expert Consensus Writing Group on ApoE ε4 and Alzheimer's Disease, Neurodegenerative Disease Special Committee, China Association for Promotion of Health Science and Technology, Yantai Regional Sub Center of China National Clinical Research Center for Neurological Diseases. Expert consensus on the standardized application of ApoE ε4 measurement in Alzheimer's disease [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(8): 657-667.
[6]	Feng ZHANG, Fan-gang MENG. Research progress of subthalamic nucleus deep brain stimulation in treatment of autonomic nerve dysfunction in Parkinson's disease [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(7): 510-515.
[7]	Gui-zhi WU, Hong TIAN. Clinical research progress of deep brain stimulation for Meige's syndrome [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(7): 516-521.
[8]	Fan-gang MENG, Jian-guo ZHANG. Application of retroauricular bone grinding groove technology in deep brain stimulation [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(7): 522-524.
[9]	Lin CHEN, Hua PAN. Electrophysiological diagnosis of functional tremor [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(7): 573-578.
[10]	Jun-ji WEI, Jian-bo CHANG. Promoting the concept of neurosurgical critical care in primary hospitals [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(6): 403-406.
[11]	Ruo-lin SHI, Xiu-jie GAO, Jia-ning CUI, Yan SHAO, Lu-shuang XIE, Yi LIU. Advance on association between 5-hydroxytryptamine and non-motor symptoms in Parkinson's disease [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(6): 497-501.
[12]	Hai-feng LI. Glucocorticoids remain the basis for treatment of myasthenia gravis in the era of targeted therapies [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(5): 295-307.
[13]	Hong-jia XU, Ya-qing SHU, Pin WANG, Fan LI, Shun-liang XU, Wei QIU, Xiao-yu MA. Advances on the diagnosis and treatment of aquaporin 4 antibody positive neuromyelitis optica spectrum disorders [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(5): 308-314.
[14]	Yu HUANG, Jin-chi LIAO, Ya-qing SHU. Progress on sleep disorders in anti-N-methyl-D-aspartate receptor encephalitis [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(5): 315-319.
[15]	Cai-yun LIU, Tao JIN. Immunotherapeutic potential of dendritic cells in multiple sclerosis [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(5): 320-330.

模态框（Modal）标题

Please choose a citation manager

Content to export

The situations and strategies of amyloid-β-directed passive immunotherapy for Alzheimer's disease

β-淀粉样蛋白被动免疫治疗阿尔茨海默病的现状与策略

RichHTML

PDF

Knowledge

Cited

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments